Drug Database · Clinicians

Guaifenesin + Pseudoephedrine

Also known as: guaiphenesin (former British name, for guaifenesin)

Brands (1) Robitussin PSShow all

US brand (reference label): Mucinex D; not a Philippine-registered brand.

Expectorant US FDA class
Decongestant/Expectorant PH FDA category
Fixed-dose combination.

S2 · Dangerous drug — PDEA S2 license required; see prescription rules belowOTC · Over-the-counter1 PH product

Philippine Schedule (DDB BR 4 s.2005 as amended by BR 1 s.2018); Philippine Schedule 5; also 1988 Convention Table I; PDEA S-2 license required. Never sold over the counter or distributed as physician's samples (BR 4 s.2005 Sec. 4). Philippine Schedule 5 (BR 1 s.2014 Sec. 2(2)): oral FDA-registered preparations by ordinary prescription in triplicate (Sec. 4(4)(a)); injectables on the DOH Special Prescription Form (yellow). Until June 30, 2027, S-2 licensed practitioners may use an ordinary prescription in triplicate instead of the special form (one dangerous drug per prescription, "NO REFILL", up to 30 days; 60 days for Philippine Schedule 4 drugs in epilepsy and dystonia) (BR 10 s.2025, extended by BR 5 s.2026).; BR 4 s.2005 Sec. 2 exempts a preparation from classification as a dangerous drug only if it is compounded to present negligible abuse risk, the ephedrine/pseudoephedrine cannot be readily extracted, it contains enough other non-narcotic active ingredient to prevent potentiation, it has no narcotic or psychotropic substance, and it is not injectable. BR 1 s.2018 later amended Sec. 1 to cover "any material, compound, mixture or preparation containing the same" and did not restate Sec. 2. Whether a given combination holds a DDB exemption is product-specific (BR 1 s.2014 Sec. 4(9)); the OTC ban in Sec. 4 applies regardless. Source: DDB, Updated Lists of Scheduled Controlled Substances (as of 20 July 2026); DDB Board Regulation No. 4, s. 2005 (ephedrine and pseudoephedrine reclassified as dangerous drugs); DDB Board Regulation No. 1, s. 2018 (amending BR 4 s. 2005: isomers, halogenated and alkylated forms); DDB Board Regulation No. 1, s. 2014 (amending BR 3 s. 2003: licensing, prescriptions, exemptions); DDB Board Regulation No. 10, s. 2025 (temporary authorization of ordinary prescriptions for dangerous drugs); DDB Board Regulation No. 5, s. 2026 (ordinary prescriptions for dangerous drugs extended to June 30, 2027).

Dispensing: Over-the-counter (OTC) · Dangerous drug (S2) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID d5f046c0-66b9-4cdc-9a1e-8e2cb5ece84f, version date May 27, 2026 (Mucinex D · Reckitt Benckiser LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Uses helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive temporarily relieves nasal congestion due to: common cold hay fever…
US FDA label
Full indications and usage US FDA label

Uses helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive temporarily relieves nasal congestion due to: common cold hay fever upper respiratory allergies temporarily restores freer breathing through the nose promotes nasal and/or sinus drainage temporarily relieves sinus congestion and pressure

Dosing: Adult

Dosage and administration (US label) US FDA label

Directions do not crush, chew, or break extended-release tablet take with a full glass of water this product can be administered without regard for timing of meals adults and children 12 years and older: 2 extended-release tablets every 12 hours; not more than 4 extended-release tablets in 24 hours children under 12 years of age: do not use

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosage forms

Philippines

  • Syrup: 200 mg/60 mg per 10 mL

Registered products in the Philippines

1 product registered with the Food and Drug Administration (FDA) Philippines list Guaifenesin + Pseudoephedrine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

Philippine FDA-registered products for Guaifenesin + Pseudoephedrine
Package insert
Robitussin PSGuaifenesin/Pseudoephedrine Hydrochloride
200 mg/60 mg per 10 mL SyrupBoston Round Amber Glass Bottle x 100 mL and 200 mL (Box of 1's)
OTC
Interphil Laboratories,IncPhilippines
Trader: Pfizer Consumer Healthcare Pty. Ltd.
DR-XY31528 (FOR EXPORT ONLY)
Mar 7, 2031

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

Warnings Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product.

Ask a doctor before use if you have heart disease high blood pressure thyroid disease diabetes trouble urinating due to an enlarged prostate gland persistent or chronic cough such as occurs with smoking, asthma, chronic bronchitis, or emphysema cough accompanied by too much phlegm (mucus) When using this product do not use more than directed Stop use and ask a doctor if you get nervous, dizzy, or sleepless symptoms do not get better within 7 days, come back or occur with a fever, rash, or persistent headache. These could be signs of a serious illness.

If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Mucinex D · Reckitt Benckiser LLC [US FDA-approved label, version 11, May 27, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5f046c0-66b9-4cdc-9a1e-8e2cb5ece84f
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .